AKT1 and neoplasm: CUDC-907, a dual inhibitor of HDACs and the phosphatidyl inositol-3 kinase (PI3K)/AKT pathway, suppressed tumor growth by decreasing the expression levels of HDAC2, p-AKT, and p-ERK1/2 [68].